The albumin fusion technology helps manufacture novel next-generation protein drugs by fusing the gene that expresses human serum albumin (HAS) to the gene that expresses a therapeutically active protein or peptide.

Administration of those drugs once 5 days or once weekly to patients has longer duration of action than daily non-fused therapeutic protein treatment.

Albutropin injection is efficacious for such diseases as pituitary dwarfism, growth hormone deficiency and Turner's syndrome and albuthyrin injection has a special virtue for malacosteon and osteoporosis.

Ri Myong Hak, section chief of the Institute, told KCNA that the institute acquired with its own efforts the albumin fusion technology, an exclusive property of a few countries. Those albumin fusion proteins, developed with the technology, may provide patients with long-acting treatment options that may offer more convenient dosing regime, he added.